

SEQUENCE LISTING

<110> Sokoll, Kenneth K.

<120> Stabilized Synthetic Immunogen Delivery System

<130> Immunogen Delivery System

<160> 11

<170> PatentIn version 3.1

<210> 1

<211> 32

<212> DNA

<213> Artificial Sequence

<220>

<223> synthetic oligonucleotide

<400> 1
tcgtcgaaaa gtcgttttgt cgttttgcgtt
32

<210> 2

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> synthetic oligonucleotide

<220>

<221> misc_feature

<222> (1)..(1)

<223> n indicates phosphorothioate group

<400> 2
ntcgtcgaaaa tgtcgaaaa tcgtt
25

<210> 3

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> synthetic oligonucleotide

<400> 3

tcgtcgaaaa gtcgttttgt cgaa
24

<210> 4

<211> 50

<212> PRT

<213> Human

<220>

<221> misc_feature

<222> (20)..(20)

<223> Xaa indicates epsilon-Lys

<400> 4

Ile Ser Ile Thr Glu Ile Lys Gly Val Ile Val His Arg Ile Glu Thr
1 5 10 15Ile Leu Phe Xaa Cys Asn Gln Gly Ser Phe Leu Thr Lys Gly Pro Ser
20 25 30Lys Leu Asn Asp Arg Ala Asp Ser Arg Arg Ser Leu Trp Asp Gln Gly
35 40 45

Asn Cys

50

<210> 5

<211> 50

<212> PRT

<213> Human

<220>

<221> misc_feature

<222> (20)..(20)

<223> Xaa indicates epsilon-Lys

<400> 5

Lys Lys Lys Thr Asp Arg Val Ile Glu Val Leu Gln Arg Ala Gly Arg
1 5 10 15

Ala Ile Leu Xaa Cys Asn Gln Gly Ser Phe Leu Thr Lys Gly Pro Ser
20 25 30

Lys Leu Asn Asp Arg Ala Asp Ser Arg Arg Ser Leu Trp Asp Gln Gly
35 40 45

Asn Cys
50

<210> 6
<211> 31
<212> PRT
<213> Human

<220>
<221> misc_feature
<222> (20)..(20)
<223> Xaa indicates epsilon-Lys

<400> 6

Ile Ser Ile Thr Glu Ile Lys Gly Val Ile Val His Arg Ile Glu Thr
1 5 10 15

Ile Leu Phe Xaa Cys His Ala Ser Ile Tyr Asp Phe Gly Ser Cys
20 25 30

<210> 7
<211> 27
<212> PRT
<213> Human

<400> 7

Lys Lys Gln Tyr Ile Lys Ala Asn Ser Lys Phe Ile Gly Ile Thr Glu

1

5

10

15

Leu Glu His Trp Ser Tyr Gly Leu Arg Pro Gly
20 25

<210> 8
<211> 45
<212> PRT
<213> Human

<400> 8

Thr Ala Lys Ser Lys Lys Phe Pro Ser Tyr Thr Ala Thr Tyr Gln Phe
1 5 10 15

Gly Gly Phe Phe Leu Leu Thr Arg Ile Leu Thr Ile Pro Gln Ser Leu
20 25 30

Glu Gly Gly Glu His Trp Ser Tyr Gly Leu Arg Pro Gly
35 40 45

<210> 9
<211> 45
<212> PRT
<213> Human

<400> 9

Thr Ala Lys Ser Lys Lys Phe Pro Ser Tyr Thr Ala Thr Tyr Gln Phe
1 5 10 15

Gly Gly Leu Ser Glu Ile Lys Gly Val Ile Val His Arg Leu Glu Gly
20 25 30

Val Gly Gly Glu His Trp Ser Tyr Gly Leu Arg Pro Gly
35 40 45

<210> 10
<211> 44
<212> PRT

<213> Human

<220>

<221> misc_feature

<222> (19)..(19)

<223> Xaa indicates epsilon-Lys

<400> 10

Lys Lys Lys Ile Ile Thr Ile Thr Arg Ile Ile Thr Ile Ile Thr Thr
1 5 10 15

Ile Asp Xaa Cys Gly Glu Thr Tyr Gln Ser Arg Val Thr His Pro His
20 25 30

Leu Pro Arg Ala Leu Met Arg Ser Thr Thr Lys Cys
35 40

<210> 11

<211> 45

<212> PRT

<213> Human

<220>

<221> misc_feature

<222> (20)..(20)

<223> Xaa indicates epsilon-Lys

<400> 11

Ile Ser Ile Thr Glu Ile Lys Gly Val Ile Val His Arg Ile Glu Thr
1 5 10 15

Ile Leu Phe Xaa Cys Gly Glu Thr Tyr Gln Ser Arg Val Thr His Pro
20 25 30

His Leu Pro Arg Ala Leu Met Arg Ser Thr Thr Lys Cys
35 40 45